# Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

> **NCT01968551** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 158 (actual)

## Conditions studied

- HIV-1
- HIV Infections
- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** E/C/F/TAF
- **DRUG:** DRV
- **DRUG:** Baseline DRV- containing ARV regimen

## Key facts

- **NCT ID:** NCT01968551
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-03
- **Primary completion:** 2015-07-21
- **Final completion:** 2016-07-09
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01968551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01968551, "Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01968551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*